XVIVO launches the XPS™ system in Europe
XVIVO Perfusion is launching its newly developed appliance for lung perfusion, XPS™ (Xvivo Perfusion System), in Europe on the basis of good clinical results and great interest from clinics.
Since 2009, XVIVO Perfusion AB (publ) has developed and sought patents for a complete system for the evaluation of lungs (EVLP) so as to facilitate use of STEEN Solution™. XPS™ also contains a ventilator and will be marketed with accompanying specially adapted disposable products. By increasing the number of lungs available for transplantation, more patients with severe lung disease can be given a longer and better quality of life.
XPS™ has been developed in contact with Toronto General Hospital and according to their successful clinical development of EVLP. It has now been successfully used for two years at leading transplant centers in the USA within the framework of the NOVEL study. EVLP together with STEEN Solution™ following the Toronto protocol has already been used in more than 80 lung transplantations at many leading centers in Europe and more than 200 transplants worldwide, saving lungs that otherwise would not have been used. The XPS™ will make the EVLP procedure easier to perform, demand less time to set up and use fewer personnel than would a manually performed EVLP.
XPS™ is based on innovative technology from leading companies such as Maquet (Getinge) and Hamilton Medical and it is planned to receive a CE mark during the first quarter of 2014 together with the accompanying disposable products.
“So far we have held back on a decision to launch the XPS™ in Europe, but bearing in mind the very good clinical results and the great interest that we have noted from clinics in Europe, we are now working on a market introduction in Europe,” says XVIVO Perfusion’s CEO, Dr. Magnus Nilsson.
October 18, 2013
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, tel: +46 31 788 21 59, e-mail: firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 18, 2013 at 10:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com